DRUG PROFILE
Name : Pimavanserin
Structure :
renal impairment (CrCl < 30 mL/min). ... ➢ The elimination half-life of pimavanserin and its
Half life : Pimavanserin and its major active N-desmethylated metabolite AC-279 have
demonstrated a time to maximum plasma concentration of six hours (range, four to 24 hours)
with mean plasma half-lives of approximately 57 hours for pimavanserin and 200 hours for AC-
279.
Toxicity : Pimavanserin may increase the central nervous system depressant (CNS
depressant) activities of Atropine. The risk or severity of adverse effects can be increased when
Pimavanserin is combined with Azaperone. The risk or severity of adverse effects can be
increased when Pimavanserin is combined with AZD-3043.